Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

July 27, 2011 13:12 ET

Two Patent Grants Add to Stem Cell Therapeutics Corp. Patent Portfolio and Expand Geographic Coverage of Key Stem Cell Technologies

CALGARY, ALBERTA--(Marketwire - July 27, 2011) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Company") is pleased to announce that it has received notification of the issuance of two additional patents. The first entitled "Use of Luteinizing Hormone (LH) and Chorionic Gonadotropin (hCG) for Proliferation of Neural Stem Cells and Neurogenesis" and was granted by the Australian Patent office; Patent number 2005211847. The second is entitled "Production of Radial Glial Cells" and was issued by the Canadian Intellectual Property Office; Patent number, 2,364,095.

The first patent expands the geographical coverage of SCT's core neurogenesis technology for increasing neural stem cell numbers, or neurogenesis, by using human chorionic gonadotropin (hCG). The technology can be used either directly by administration of a therapeutic dose of drug or in the laboratory to expand the numbers of cells that would later be transplanted into a patient or an animal to induce regeneration of neural tissue in the setting of neurodegenerative disease. This patent is the basis for SCT's NTx®-265 therapy.

The second patent protects our exclusive use of specific compounds to induce neurogenesis by identifying radial glial cells (RCGs) as a potentially key central cell type within the neurogenesis process. During early growth RCGs function as neural progenitors in the developing central nervous system (CNS). This discovery and patent anticipates that proper maturation and migration of neuronal precursors will require RCGs to recapitulate development processes normally quiescent in the 'adult' mammalian brain. Importantly, RCGs are expected to be crucial for the regeneration of damaged or diseased central nervous system tissue. Similar to the first patent, direct administration of drug or expansion of cells for transplantation is protected in all CNS neurodegenerative diseases and more specifically, Alzheimer's disease, Multiple Sclerosis, Huntington's disease Amyotrophic Lateral Sclerosis or Parkinson's disease.

"SCT's investment in, and commitment to these novel regenerative medical therapies continues to yield an ever stronger and broader patent portfolio.". Said Dr. Allen Davidoff, Chief Scientific Officer of Stem Cell Therapeutics Corp. "We are pleased with the steady growth of our patent portfolio during the recent past and look forward to issuance of additional patents from our various applications over the near future.

SCT's intellectual property portfolio continues to be a key asset for the company and a coveted, industry-leading technology asset in regenerative medicine. "

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as stroke, traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information